Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Nov 2023
Takeda receives US FDA approval of Fruzaqla (fruquintinib) for previously treated metastatic colorectal cancer
8 November 2023 - Fruzaqla is the first targeted therapy approved for metastatic colorectal cancer regardless of biomarker status or ...
Posted by Michael Wonder on 09 Nov 2023
Paddy Gower has issues: blind, solo mum desperate for PHARMAC to fund life-changing medicine so she can see her kids
8 November 2023 - We sat in a field of wild daisies. Bright white and yellow against a backdrop of ...
Posted by Michael Wonder on 09 Nov 2023
PHARMAC asked to reconsider funding RSV drug for at risk babies
9 November 2023 - Paediatricians and neonatal experts are pleading with PHARMAC to rethink its decision to stop funding a ...
Posted by Michael Wonder on 09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (9 November 2023)
9 November 2023 - Two more documents are now available. ...
Posted by Michael Wonder on 08 Nov 2023
First electronic product information published for selected human medicines
8 November 2023 - The Heads of Medicines Agencies (HMA), the European Commission and EMA have published for the first time ...
Posted by Michael Wonder on 08 Nov 2023
Samsung Bioepis & Organon announce FDA acceptance of supplemental biologics license application for interchangeability designation for Hadlima (adalimumab-bwwd), a biosimilar to Humira
7 November 2023 - Supplemental biologics license application based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: ...
Posted by Michael Wonder on 08 Nov 2023
FDA approves new medication for chronic weight management
8 November 2023 - Today, the US FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body ...
Posted by Michael Wonder on 08 Nov 2023
Biogen-Sage Therapeutics post partum depression pill priced at $15,900
7 November 2023 - Sage Therapeutics has priced the oral post partum depression pill it developed with partner Biogen at ...
Posted by Michael Wonder on 08 Nov 2023
Gilead Sciences Korea seeks reimbursement for Trodelvy
8 November 2023 - Gilead Sciences Korea is seeking insurance coverage of its new drug Trodelvy (sacituzumab govitecan) for the ...
Posted by Michael Wonder on 08 Nov 2023
MHRA authorises enzyme inhibitor anastrozole to prevent breast cancer in post-menopausal women
6 November 2023 - Anastrozole is now authorised as a preventative treatment for post-menopausal women at moderate or high risk of ...
Posted by Michael Wonder on 08 Nov 2023
PHARMAC publishes agenda for November 2023 PTAC meeting
8 November 2023 - Another underwhelming agenda; yet again there is no application for a cancer medicine. ...
Posted by Michael Wonder on 08 Nov 2023
Zydus receives US FDA approval for Zituvimet to treat adult patients with type 2 diabetes mellitus
6 November 2023 - The company received final approval from the US FDA for its new drug application for Zituvimet ...
Posted by Michael Wonder on 08 Nov 2023
PHARMAC proposing to fully fund testosterone gel for all who need it
8 November 2023 - PHARMAC is consulting on a proposal to fund testosterone gel without restrictions as an additional testosterone ...
Posted by Michael Wonder on 08 Nov 2023
Janssen submits Phase 3 study data to the European Medicines Agency and US Food and Drug Administration for Sirturo (bedaquiline)
7 November 2023 - STREAM Stage 2 study data submitted as part of type II variation to the EMA and supplemental ...
Posted by Michael Wonder on 08 Nov 2023
Mitsubishi Tanabe Pharma Canada announces that Company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in Prince Edward Island, Newfoundland and Labrador
7 November 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the Prince ...